Employees: 382
Size Nxera Pharma (4565.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $974M, the 751st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,708 on 18 Nov 2026.
Performance Over six months the shares gained 45.7%, against -11.1% for the median peer and -1.4% for the Japan market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 23.7% over the last twelve months (peer median +2.8%); the operating margin is 13.6% (peer median 8.7%).
Valuation It trades at 25.8× forward earnings against a peer median of 20.6× (4th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.2 points below its cost of capital (5.5% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥35.5B | ¥29.6B | ¥28.8B | ¥12.8B | ¥15.6B |
| Revenue growth | — | +3% | +126% | -18% | — |
| Gross profit | ¥28.1B | ¥18.0B | ¥18.1B | ¥7.87B | ¥13.8B |
| EBITDA | ¥9.17B | -¥3.71B | -¥1.38B | -¥6.58B | ¥4.16B |
| Net income | -¥5.39B | -¥12.5B | -¥4.84B | -¥7.19B | ¥382M |
| Free cash flow | ¥5.01B | -¥3.12B | -¥8.24B | -¥6.08B | ¥9.68B |
| Capital expenditure | ¥5.85B | ¥625M | ¥1.54B | ¥851M | ¥303M |
| Total debt | ¥52.0B | ¥57.4B | ¥67.9B | ¥74.0B | ¥29.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4565.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +40.5% | -6.5% | highest of 21 |
| 6-month return | +45.7% | -11.1% | highest of 21 |
| Distance from 52-week high | -9.1% | -35.0% | 2nd highest of 21 |
| Revenue growth (TTM) | +23.7% | +2.8% | 4th highest of 19 |
| Operating margin | 13.6% | 8.7% | 7th highest of 19 |
| Forward P/E | 25.8× | 20.6× | 4th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 17.7% | 6.0% | most demanding of 13 |
| Growth delivered (Del g) | +27.3% | +2.6% | highest of 13 |
| Hurdle (Req g minus delivered) | -9.7 pp | +1.8 pp | 2nd least demanding of 13 |
| ROIC minus cost of capital | -2.2 pp | -0.8 pp | 6th lowest of 19 |
| EV / EBITDA | 20.8× | 11.1× | most expensive of 6 |
| Net debt / EBITDA | 3.9× | 1.8× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 25.8× | 17.7% | +27.3% |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 21.4× | n/a | n/a |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 12.5× | 2.3% | -0.5% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 15.9× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 42.3× | 11.6% | +4.9% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | n/a | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | n/a | 10.3% | -13.7% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |